Analysis Tools
mortality/aging
|
• when treated with doxycycline during the first week of life, mice die within the first 2 weeks of life unlike similarly treated Tg(Myh6*/tetO-Capn1)L1Gwd
• when treated with doxycycline at 8 weeks of age, most mice die within 4 weeks unlike similarly treated Tg(Myh6*/tetO-Capn1)L1Gwd
|
cardiovascular system
|
• when treated with doxycycline at 8 weeks of age
|
|
• at 12 weeks and further at 20 weeks when treated with doxycycline at 8 weeks of age
|
|
• following neonatal induction with doxycycline, mice exhibit increased left ventricular end-systolic dimension compared with wild-type mice
|
|
• when treated with doxycycline at 8 weeks of age
|
|
• following neonatal induction with doxycycline
|
|
• when treated with doxycycline at 8 weeks of age
|
|
• following neonatal induction with doxycycline, mice exhibit generalized mononuclear cell infiltrate unlike wild-type mice
|
immune system
|
• following neonatal induction with doxycycline, mice exhibit generalized mononuclear cell infiltrate unlike wild-type mice
|
muscle
|
• when treated with doxycycline at 8 weeks of age
|
|
• following neonatal induction with doxycycline
|
growth/size/body
|
• at 12 weeks and further at 20 weeks when treated with doxycycline at 8 weeks of age
|
cellular
|
• when treated with doxycycline at 8 weeks of age
|
